Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/10/2793450/31990/en/Agios-Presents-Positive-Results-from-Phase-2-Portion-of-the-RISE-UP-Pivotal-Study-in-Sickle-Cell-Disease-at-65th-ASH-Annual-Meeting-and-Exposition.html

– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo –

– Improvements Observed in Annualized Rates of Sickle Cell Pain Crises, Markers of Hemolysis and Erythropoiesis in Participants Treated with Mitapivat –

Read more at globenewswire.com

Related news for (AGIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.